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Abstract Inflammation is an essential aspect of innate immunity but also contributes to diverse
human diseases. Although much is known about the kinases that control inflammatory signaling,
less is known about the opposing phosphatases. Here we report that deletion of the gene
encoding PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) protects mice from lethal
lipopolysaccharide (LPS) challenge and live Escherichia coli infection. Investigation of PHLPP1
function in macrophages reveals that it controls the magnitude and duration of inflammatory
signaling by dephosphorylating the transcription factor STAT1 on Ser727 to inhibit its activity,
reduce its promoter residency, and reduce the expression of target genes involved in innate
immunity and cytokine signaling. This previously undescribed function of PHLPP1 depends on a
bipartite nuclear localization signal in its unique N-terminal extension. Our data support a model in
which nuclear PHLPP1 dephosphorylates STAT1 to control the magnitude and duration of
inflammatory signaling in macrophages.
DOI: https://doi.org/10.7554/eLife.48609.001
Introduction
Gene expression is an exquisitely regulated process that maintains cellular homeostasis and orches-
trates appropriate responses to environmental stimuli such as hormones, cytokines, and pathogenic
microbes (Dawson and Kouzarides, 2012; Flavahan et al., 2017). Homeostatic control of inflamma-
tory genes is particularly relevant to cancer since chronic inflammation promotes tumorigenesis and
influences patient response to cancer therapeutics (Coussens and Werb, 2002; Grivennikov et al.,
2010). Dysregulated gene expression, a hallmark of cancer, can arise from mutations in transcription
factors (exemplified by p53; see Sabapathy and Lane, 2018), alterations in signaling pathways con-
trolling transcription factor function (for example, hormone-dependent transcription factors in pros-
tate and breast cancers; see Jernberg et al., 2017; Pejerrey et al., 2018), or upregulation of
oncogenic transcription factors (notably c-myc, which regulates essential cell-cycle checkpoints;
see Kalkat et al., 2017). Aberrant protein phosphorylation underpins all of these mechanisms, via
dysregulation of signaling pathways, alterations in transcription factor machinery, and/or effects on
the chromatin epigenetic landscape (Rossetto et al., 2012; Whitmarsh and Davis, 2000). Thus, tar-
geting phosphorylation mechanisms is of considerable therapeutic interest.
Macrophages are among the first responders to infection, engaging foreign pathogens via pat-
tern recognition receptors, including the Toll-like receptors (TLRs). TLRs are a conserved family of
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cell surface or phagosome-associated receptors that discriminate distinct features of microbial and
viral pathogens, including lipoproteins (TLR1/2/6), lipopolysaccharide (LPS) (TLR4), flagellin (TLR5),
single-stranded RNA (TLR7/8), double-stranded RNA (TLR3), and double-stranded DNA (TLR9)
(Karin et al., 2006; O’Neill et al., 2013). Upon pathogen recognition by TLRs, a pro-inflammatory
response is initiated that activates the signal-dependent transcription factors nuclear factor-k B
(NFkB), activator protein 1 (AP1), interferon response factors (IRFs), and, through secondary mecha-
nisms, the signal transducer and activator of transcription (STAT) protein family (O’Neill et al.,
2013). These activated transcription factors function in a combinatorial manner to drive expression
of antimicrobial and inflammatory response genes that aid in elimination of foreign pathogens. How-
ever, while inflammation is required for protection against foreign microbes, it can lead to excessive
cytokine production, chronic inflammation, and cancer if not properly resolved (Coussens and
Werb, 2002; Fullerton and Gilroy, 2016; Grivennikov et al., 2010). Thus, macrophages have
evolved regulatory mechanisms to resolve inflammatory responses in a timely manner, including shut
down of STAT1 signaling pathways by the suppressor of cytokine signaling (SOCS) family of proteins
(O’Shea and Murray, 2008), suppression of nitric oxide production by the enzyme arginase
(Wynn and Vannella, 2016), and inhibition of a key subset of NFkB-dependent genes by anti-inflam-
matory omega-3 fatty acids (Oishi et al., 2017).
STAT1 is the founding member of the STAT transcription factor family and serves as a paradigm
for how phosphorylation regulates transcription factor structure, function, and localization
(Darnell et al., 1994; Morris et al., 2018; Stark and Darnell, 2012). In the canonical pathway,
STATs are recruited from the cytosol to cytokine-bound and Tyr-phosphorylated receptors where
they are phosphorylated on a key Tyr residue (Tyr701 for STAT1) by Janus Kinases (JAKs). This phos-
phorylation event promotes STAT dimerization and nuclear entry, allowing STAT binding to specific
promoter sequences and thus initiating gene transcription. Upon promoter binding, STATs become
additionally phosphorylated on a regulatory Ser residue at a MAPK consensus sequence (Ser727 for
STAT1), a modification that enhances their transcriptional activity (Darnell, 1997; Sadzak et al.,
2008; Wen et al., 1995b; Whitmarsh and Davis, 2000). Importantly, STAT1 transduces signals from
type I and II interferons (IFNs), resulting in binding to IFN-stimulated response elements (ISREs) and
to IFN-gamma (IFNg )-activated site (GAS) elements in the promoters of IFN-stimulated genes (ISGs),
inducing their transcription and stimulating inflammation (Platanias, 2005). While the kinases that
phosphorylate Tyr701 and Ser727 on STAT1 have been extensively studied, as have been the phos-
phatases that dephosphorylate Tyr701, the phosphatases that oppose the Ser727 phosphorylation
are unknown.
PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) is one of the newest members of
the phosphatome (Chen et al., 2017; Gao et al., 2005). Originally discovered for its function in sup-
pressing growth factor signaling by dephosphorylating Akt on the hydrophobic motif site, Ser473
(Gao et al., 2005), the repertoire of PHLPP1 substrates is continually expanding (Grzechnik and
Newton, 2016). PHLPP1 is a bona fide tumor suppressor: its expression is frequently lost in cancer
and its genetic ablation in a mouse model results in prostate neoplasia (Chen et al., 2011; Liu et al.,
2009). PHLPP1 is also involved in the immune response, where its dephosphorylation of Akt reduces
the capacity of regulatory T cells to transduce T cell receptor signals, a key function in T cell devel-
opment (Patterson et al., 2011). Additionally, mice lacking PHLPP1 have enhanced chondrocyte
proliferation as a result of increased Akt2 activity, diminished FoxO1 levels, and increased Fgf18
expression, suggesting PHLPP1 inhibition could be a strategy to promote cartilage regeneration and
repair (Bradley et al., 2015). PHLPP1 also suppresses receptor tyrosine kinase gene expression by a
mechanism distinct from its effects on Akt, to influence growth factor signaling, including that medi-
ated by the epidermal growth factor (EGF) receptor (Reyes et al., 2014).
PHLPP1 is unusual among protein phosphatases in that its regulatory modules and catalytic
domain are on the same polypeptide. Most notably, it has a PH domain essential for dephosphoryla-
tion of protein kinase C (PKC) (Gao et al., 2008), a PDZ ligand necessary for Akt recognition
(Gao et al., 2005), and a leucine-rich repeat (LRR) segment required for transcriptional regulation of
receptor tyrosine kinases (Reyes et al., 2014). In addition, PHLPP1 possesses an approximately 50
kDa N-terminal extension (NTE) of unknown function. Stoichiometric association with substrates by
direct binding to the protein-interaction domains on PHLPP or common scaffolds (e.g. PDZ domain
proteins such as Scribble; see Li et al., 2011) allows fidelity and specificity in PHLPP function, and
may account for its > 10 fold lower catalytic rate compared to the closely related phosphatase
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PP2Ca (Sierecki and Newton, 2014). Given its transcriptional regulation of at least one family of
genes (Reyes et al., 2014), PHLPP1 is an attractive pharmacological target for modulation of gene
expression.
Here we report that nuclear-localized PHLPP1 opposes STAT1 Ser727 phosphorylation to inhibit
its transcriptional activity and promote normal resolution of inflammatory signaling. We find that
Phlpp1-/- mice have improved survival following infection with Escherichia coli (E. coli), indicating a
role of the phosphatase in innate immunity. Since macrophages are key in the initial response to
lipopolysaccharide (LPS) from Gram-negative bacteria such as E. coli, we further explored the role of
PHLPP1 in controlling LPS-dependent signaling in this cell type. The STAT1 binding motif was identi-
fied from the most common promoter sequences of 199 genes that remained elevated following
LPS treatment of bone marrow-derived macrophages (BMDMs) from Phlpp1-/- mice compared to
those from wild-type (WT) mice. We validated common transcriptional targets of PHLPP1 and
STAT1, showing that loss of PHLPP1 upregulates the transcription of several genes including guany-
late binding protein 5 (Gbp5), whereas loss of STAT1 downregulates them. Cellular studies revealed
that dephosphorylation of STAT1 on Ser727 suppresses its transcriptional activity by a mechanism
that depends both on the catalytic activity of PHLPP1 and a previously undescribed nuclear localiza-
tion signal (NLS) in the NTE of PHLPP1. Taken together, our results identify PHLPP1 as a major
player in the resolution of inflammatory signaling.
Results
PHLPP1 regulates the innate immune response
To explore the role of PHLPP1 in acute inflammation, we examined the kinetics and outcome of sep-
sis-induced death caused by intraperitoneal (i.p.) injection of Gram-negative E. coli bacteria in WT
and Phlpp1-/- mice. Surprisingly, absence of PHLPP1 provided a strong protective effect; at a dose
where more than 50% of WT mice died within 12 hr of E. coli challenge, 50% of the Phlpp1-/- mice
remained alive after 10 days (Figure 1A). Similarly, Phlpp1-/- mice were protected from toxicity
induced by the purified Gram-negative bacterial cell wall component LPS, with nearly half of the
Phlpp1-/- mice alive after 10 days compared to only 1 out of 16 of the WT mice (Figure 1B). To
understand the lower mortality rates in Phlpp1-/- mice, we measured levels of different cytokines in
the serum of mice across a time course following LPS injection (Figure 1C–E). Serum levels of pro-
inflammatory cytokine interleukin 6 (IL-6) were significantly increased in WT mice within 5 hr of LPS
injection, returning to baseline within 12 hr (Figure 1C). In contrast, the Phlpp1-/- mice had 2-fold
lower IL-6 levels at 5 hr post-infection, but these levels were sustained for up to 24 hr, suggestive of
improper resolution of inflammation. Levels of another pro-inflammatory cytokine, IL-1b, were like-
wise consistently higher in Phlpp1-/- mice compared with WT mice (Figure 1D). By contrast, levels of
the anti-inflammatory cytokine IL-10 did not differ significantly between the WT and Phlpp1-/- mice
(Figure 1E). Note that cytokine levels were measured up to 24 hr post LPS injection, when the pro-
tective effect of PHLPP1 loss was not yet apparent. These findings indicate an essential role for
PHLPP1 in regulation of the innate immune response at the whole organism level.
Loss of PHLPP1 results in increased STAT1-dependent transcription in
macrophages
Since macrophages are a key cell type involved in the initial response to E. coli infection and LPS
challenge, we analyzed the transcriptome of BMDMs isolated from WT or Phlpp1-/- mice before and
after stimulation by the major LPS component, Kdo2-Lipid A (KLA), for 1, 6, or 24 hr (Figure 2A).
RNA-Seq analysis identified 1,654 mRNA transcripts induced more than two-fold by KLA treatment,
with a false discovery rate (FDR) less than 0.05 at any of the time points. Expression of approximately
12% of these genes (199 genes; Supplementary file 1) was increased in macrophages from Phlpp1-/-
mice compared to those from littermate control WT mice 6 hr following KLA treatment; transcript
levels of these genes remained significantly elevated (>two fold) 24 hr later. Another set of genes
exhibited reduced expression 24 hr following KLA treatment (144 genes; Supplementary file 2).
Gene ontology analysis revealed that many of the genes whose expression was elevated in the
Phlpp1-/- macrophages are associated with inflammatory signaling: these included genes annotated
for their involvement in the innate immune response, cytokine-cytokine receptor interactions, LPS
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signaling, interferon-b response, and tumor necrosis factor (TNF) signaling-dependent pathways
(Figure 2B). Genes significantly decreased in Phlpp1-/- compared to WT macrophages were enriched
most significantly in nodes related to central carbon metabolism, and to a lesser extent, chronic
inflammatory responses and LPS signaling (Figure 2B).
To gain insight into gene regulatory mechanisms affected by loss of PHLPP1, we performed de
novo motif analysis of the promoters of upregulated genes in Phlpp1-/- macrophages using Hyper-
geometric Optimization of Motif EnRichment (HOMER), a suite of tools for motif discovery and Next
Generation Sequencing (NGS) analysis (Heinz et al., 2010). This algorithm defines motifs that are
statistically enriched in a targeted promoter list compared to random promoter sequences with com-
parable GC content. The analysis revealed significant enrichment of STAT (p<10 18) and IRF
(p<10 9) motifs (Figure 2C) in the promoters of genes whose expression was statistically increased
in Phlpp1-/- macrophages compared to WT macrophages. Of the 199 genes with elevated expres-
sion, 46% of the genes had promoters with a consensus STAT binding motif, 51% had promoters
with a potential binding site for IRF family of transcription factors, and 26% had promoters with pre-
dicted binding sites for both STAT and IRF (Figure 2D). We selected for further analysis three genes
whose expression was elevated in the Phlpp1-/- compared to WT macrophages and which had proxi-
mal STAT1 binding motifs in their promoters: Cd69, Ifit2, and Gbp5. Normalized mRNA-Seq data
for each of these three genes confirmed elevated mRNA levels in Phlpp1-/- macrophages compared
to WT macrophages (Figure 2E–G). Thus, loss of PHLPP1 leads to sustained KLA-induced expression
of genes involved in inflammation, of which 46% have predicted STAT motifs in their proximal regu-
latory regions.
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Figure 1. PHLPP1 knock-out mice are protected against sepsis-induced death. (A) Survival curve of WT and Phlpp1-/- mice i.p. infected with 1  107 cfu
of E. coli. Values are expressed as percent survival of 15 mice for each genotype. **p<0.01 by log-rank test. (B) Survival curve of WT and Phlpp1-/- mice
i.p. injected with 15 mg/kg LPS. Values are expressed as percent survival of 16 mice for each genotype. *p<0.05 by log-rank test. (C–E) ELISA showing
IL-6 (C), IL-1b (D) and IL-10 (E) levels in serum at the indicated times after i.p. injection of 10 mg/kg LPS. Data represent mean ± SEM. Statistics analyzed
by Student’s t-test *p<0.05, **p<0.01.
DOI: https://doi.org/10.7554/eLife.48609.002
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If PHLPP1 suppresses STAT-regulated gene transcription, we reasoned that 1] knockdown of a
STAT family member should reduce transcription of the same genes affected by loss of PHLPP1 and
2] knockdown of PHLPP1 should enhance STAT binding to its promoters. STAT1 is required for LPS-
induced gene expression in macrophages (Ohmori and Hamilton, 2001) and implicated as a
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Figure 2. Loss of PHLPP1 modulates the expression of inflammatory genes in macrophages. (A) Heat map for mRNA-Seq expression of the 1,654
mRNA transcripts regulated greater than two-fold with a FDR < 0.05 in BMDMs isolated from WT or Phlpp1-/- animals treated with 100 ng/ml KLA for 1,
6 or 24 hr. Data represent the log2 difference between the mRNA expression in Phlpp1
-/- macrophages compared to wild-type macrophages. (B) Gene
ontology analysis for the 199 elevated (red arrow) or 144 decreased (blue arrow) transcripts in Phlpp1-/- macrophages compared to wild-type
macrophages. (C) De novo motif analysis using HOMER (Hypergeometric Optimization of Motif EnRichment) for the 199 promoters corresponding to
the genes elevated in the Phlpp1-/- macrophages. (D) Pie graph showing the percentage of promoters of elevated genes that contain STAT or IRF
binding motifs. (E–G) Normalized mRNA-Seq values for (E) Cd69 (F) Ifit2 and (G) Gbp5 mRNA in BMDMs isolated from WT or Phlpp1-/- animals treated
with 100 ng/ml KLA for 0, 1, 6, or 24 hr. RPKM – Reads Per Kilobase Million. Values are expressed as mean ± SEM. *p<0.05 (Student’s t-test) compared
to WT cells. See also Supplementary file 1 and Supplementary file 2.
DOI: https://doi.org/10.7554/eLife.48609.003
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PHLPP1 target in iNOS regulation (Alamuru et al., 2014). STAT1 knockdown by siRNA in thioglycol-
late-elicited peritoneal macrophages resulted in a 2-fold reduction in KLA-induced transcription of
Cd69, Ifit2, and Gbp5 at 6 hr compared to a control siRNA transfection, with transcript levels drop-
ping to near baseline by 24 hr (Figure 3A–C). The effect of PHLPP1 knockdown on STAT1 promoter
occupancy was examined by chromatin immunoprecipitation (ChIP) using STAT1-specific antibodies.
KLA induced STAT1 binding to the promoters of Cd69, Ifit2, and Gbp5, with maximal binding
observed 1 hr post stimulation, followed by a decay in binding to near baseline after 24 hr
(Figure 3D–F). In contrast, binding to these promoters was enhanced and sustained in Phlpp1-/-
macrophages relative to WT cells. The degree of enhancement and the kinetics of activation/resolu-
tion varied depending on the gene examined: PHLPP1 loss had the most robust early effect (1 hr) on
the Ifit2 promoter and at a later time (24 hr) on the Cd69 promoter. Thus, PHLPP1 suppresses KLA-
stimulated binding of STAT1 to its promoters and thereby reduces transcription of its target genes.
PHLPP1 binds to STAT1 and dephosphorylates Ser727
We next examined whether PHLPP1 affects the phosphorylation state of the two regulatory STAT1
phosphorylation sites, Ser727 and Tyr701. Primary BMDMs were isolated from WT and Phlpp1 -/-
mice and the kinetics and magnitude of KLA-triggered phosphorylation at each of the two STAT1
sites were compared. Loss of PHLPP1 in BMDMs led to a robust increase in STAT1 phosphorylation
on the regulatory site Ser727 but did not affect Tyr701 phosphorylation (Figure 4A–B). PHLPP1 loss
also resulted in an increase in Erk phosphorylation at its activation loop sites, as previously reported
(Reyes et al., 2014). Incubation of in vitro phosphorylated STAT1 with immunoprecipitated FLAG-
tagged PHLPP1 resulted in dephosphorylation at Ser727, suggesting that PHLPP1 directly dephos-
phorylates STAT1 (Figure 4C). Furthermore, overexpression of PHLPP1 in HEK-293T cells reduced
IFNg-dependent phosphorylation of STAT1 on Ser727 but not on Tyr701 (Figure 4D–E). Thus,
PHLPP1 selectively dephosphorylates the Ser727 regulatory phosphorylation on STAT1 in vitro and
in cells.
Because the abundance of PHLPP1 in the cell is much lower than other phosphatases such as
PP2A (Hein et al., 2015), we next sought to determine whether regulation of STAT1 promoter activ-
ity was solely due to PHLPP1 phosphatase activity or occurred in combination with other phospha-
tases. Taking advantage of the insensitivity of PHLPP phosphatases to the PP1/PP2A inhibitor
okadaic acid (OA) (Gao et al., 2005), we examined whether OA treatment affected KLA-dependent
changes on Ser727 phosphorylation in primary BMDMs from WT mice. Figure 5A–B shows that the
KLA-induced increase in Ser727 phosphorylation was relatively insensitive to OA, under conditions
where the phosphorylation of Erk (at Thr202/Tyr204) and Akt (at Thr308) was significantly increased
upon OA addition. These data are consistent with PHLPP1, a PP2C family member, being the pri-
mary regulator of phosphorylation on the activity-tuning Ser727 site of STAT1.
We next addressed whether enhanced promoter binding of STAT1 upon loss of PHLPP1 resulted
in enhanced transcriptional activation using a luciferase reporter assay. WT or Phlpp1-/- mouse
embryonic fibroblasts (MEFs) were co-transfected with a firefly luciferase reporter construct contain-
ing GAS promoter elements, as well as a renilla luciferase controlled by a constitutive CMV promoter
as an internal control. STAT1 promoter activity was assessed by monitoring luminescence following
IFNg stimulation. Figure 6A shows that STAT1 promoter activity was significantly higher in Phlpp1-/-
MEFs compared to WT MEFs at both 6 hr and 24 hr. Pre-treatment of cells with okadaic acid, under
conditions that increased the phosphorylation of PP2A-sensitive substrates (see Figure 5A and Fig-
ure 6—figure supplement 1), had no effect on STAT1 promoter activity (Figure 6A); note that treat-
ment with a PKC inhibitor also had no effect on STAT1 promoter activity (Figure 6—figure
supplement 2). Because STAT1 functions in the nucleus, we next asked whether PHLPP1 regulation
of STAT1 occurs in the cytoplasm or nucleus. To this end, we assessed the effect of expressing either
the PP2C domain of PHLPP1 or a nuclear-targeted (NLS) PP2C domain of PHLPP1 (Figure 6B) on
IFNg-induced STAT1 promoter activity via the GAS luciferase assay. The overexpressed PP2C
domain of PHLPP1 (Figure 6C, blue) was considerably less effective in inhibiting STAT1 promoter
activity compared to full-length PHLPP1 (Figure 6C, red). However, forcing the PP2C domain into
the nucleus by attaching an NLS to its N-terminus inhibited STAT1 promoter activity as effectively as
overexpression of full-length PHLPP1 (Figure 6C, orange). Analysis of the subcellular localization of
the constructs used in this experiment revealed that full-length PHLPP1 was primarily cytosolic, the
isolated PP2C domain had increased nuclear localization, and the NLS-PP2C was enriched in the
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Figure 3. PHLPP1 controls STAT1 genomic recruitment and STAT1-dependent gene expression. (A–C)
Quantitative PCR analysis for (A) Cd69 (B) Ifit2 and (C) Gbp5 mRNA isolated from thioglycollate-elicited peritoneal
macrophages treated with control siRNA (siCtl) or siRNA specifically targeting Stat1 (siStat1) and subsequently
treated with vehicle or 100 ng/ml KLA for 6 or 24 hr. Values are expressed as mean ± SEM from replicate
experiments. *p<0.05 (Student’s t-test) compared to siCtl treated cells. (D–F) Quantitative PCR analysis of ChIPs
for STAT1 at the (D) Cd69 (E) Ifit2 and (F) Gbp5 promoter in BMDMs isolated from WT or Phlpp1-/- animals and
Figure 3 continued on next page
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nucleus (Figure 6—figure supplement 3). To address whether PHLPP1 catalytic activity is required
for STAT1 regulation, we utilized a phosphatase-dead PP2C domain in which two active site resi-
dues, Asp1210 and Asp1413 (Sierecki and Newton, 2014) were mutated to Ala (DDAA). The cata-
lytically-inactive NLS-PP2C was no longer able to suppress STAT1 activity (Figure 6C, purple);
immunofluorescence confirmed its nuclear localization (Figure 6—figure supplement 3). Thus, both
the catalytic activity and nuclear localization of PHLPP1 are necessary for it to regulate STAT1 tran-
scriptional activity.
PHLPP1 has a bipartite nuclear localization signal in its N-Terminal
extension
Bioinformatics analysis of the sequence of PHLPP1 using SeqNLS (Lin and Hu, 2013) revealed a
potential Arg-rich bipartite NLS (92RRRRR-X-122RRGRLKR) in the N-terminal extension unique to the
Figure 3 continued
treated with 100 ng/ml KLA for 0, 1, 6 or 24 hr. Values are expressed as mean ± SEM. *p<0.05 (Student’s t-test)
compared to WT cells.
DOI: https://doi.org/10.7554/eLife.48609.004
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Figure 4. PHLPP1 regulates STAT1 phosphorylation on Ser727. (A) Western blot analysis of primary BMDM from WT or Phlpp1-/- mice treated with 100
ng/ml KLA for the indicated times and probed with the indicated antibodies. (B) Ratio of pSTAT1 (S727):total STAT1, pSTAT1 (Y701):total STAT1 or
phosphoERK (T202/Y204):total ERK normalized to the highest value; data represent the mean ± SEM of five independent experiments as in (A).
**p<0.01 (Student’s t-test) compared to WT cells. (C) Western blot analysis of an in vitro phosphatase assay of purified and phosphorylated STAT1 and
immunoprecipitated FLAG-PHLPP1, incubated for 0 or 120 min at 30˚C (on the left). On the right, quantification of pSTAT1 (S727) divided by total
STAT1 and normalized to 0 time point. Values are expressed as mean ± SEM of three independent experiments. **p<0.01 (Student’s t-test). (D)
Western blot analysis of HEK-293T cells over-expressing vector control (Vector) or HA-tagged PHLPP1 and treated with 10 ng/ml IFNg for 0, 1, 6, or 24
hr. (E) Graphs represent the quantification of three independent experiments as presented in (D). Values are expressed as mean relative units of
pSTAT1 (S727) or (Y701) divided by b-Actin and normalized to vector 0 hr ± SEM. *p<0.05 (Student’s t-test) compared to vector control expressing cells.
See also Figure 6—figure supplement 1.
DOI: https://doi.org/10.7554/eLife.48609.005
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PHLPP1 isozyme (Figure 6D). To test whether these basic segments function as an NLS, we exam-
ined the subcellular localization in HeLa cells of the NTE alone or NTE in which the basic residues in
each or both halves of the potential bipartite NLS were mutated to Ala (Figure 6E). Immunofluores-
cence revealed that the NTE localizes to the nucleus. Mutation of the first NLS or the second NLS
increased the distribution of the NTE to the cytosol, and mutation of both decreased the nuclear:
cytoplasmic ratio to be comparable to that of a construct of the NTE with a strong Nuclear Export
Signal (NES) (LALKLAGLDI from PKI; see Wen et al., 1995a) (Figure 6F). Full-length PHLPP1 was pri-
marily cytosolic, leading us to ask whether there may also be an NES. Bioinformatics analysis of the
primary sequence identified a potential Leu-rich NES (Xu et al., 2015) immediately following the last
LRR and preceding the phosphatase domain (Figure 6—figure supplement 4). Attachment of this
14-residue sequence to the N-terminus of the NTE resulted in distribution of the NTE to the cytosol
(Figure 6—figure supplement 4). Thus, PHLPP1 nuclear localization is controlled by a bipartite NLS
in the NTE and is opposed by an NES following the LRR. Lastly, we examined the effect of mutating
the NLS on the ability of full-length PHLPP1 to reduce STAT1 transcriptional activity as assessed
using the GAS promoter assay. The reduction in IFNg-induced STAT1 activity resulting from PHLPP1
overexpression (Figure 6G, red) was abolished upon mutation of NLS2 (Figure 6G, brown) or both
halves of the NLS (NLS1/2) (Figure 6G, purple). Mutation of NLS1 had an intermediate effect
(Figure 6G, blue). These data reveal that a bipartite NLS in the NTE of PHLPP1 localizes PHLPP1 to
the nucleus, where it suppresses the transcriptional activity of STAT1.
We next assessed which domain of PHLPP1 contributes to the observed regulation of STAT1
activity on the GAS promoter. Overexpression of full-length PHLPP1 in HEK-293T cells markedly
reduced GAS promoter activity (Figure 7A, red) compared to the vector only control (Figure 7A,
black). A construct of PHLPP1 lacking the NTE (deletion of first 512 amino acids of its N-terminus;
PHLPP1DNTE, blue) was less effective than full-length PHLPP1 in reducing STAT1 activity, whereas a
construct comprised of just the NTE (amino acids 1–512, green) caused a significant increase in GAS
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Figure 5. STAT1 Ser727 phosphorylation and transcriptional activity are insensitive to okadaic acid. (A) Western blot analysis of primary BMDMs from
WT or Phlpp1-/- mice treated with 100 ng/ml KLA for 0 or 30 min followed by treatment with 1 mM OA or DMSO control for an additional 15 min and
probed with the indicated antibodies; pAkt antibody recognizes phosphorylated Thr308. (B) Graphs represent the quantification of three independent
experiments as presented in (A). Values are expressed as the mean ± SEM of the ratio of pSTAT1 (S727) to total STAT1 normalized to the highest value;
*p<0.05, **p<0.01 and n.s.- non-significant (Student’s t-test).
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Figure 6. PHLPP1 suppresses STAT1 transcriptional activity by a mechanism that depends on its catalytic activity and an NLS in its N-Terminal
Extension. (A) Luciferase reporter assay in WT (+/+) and Phlpp1-/- (-/-) MEFs over-expressing GAS luciferase reporter and treated with 10 ng/ml IFNg for
0, 1, 6, or 24 hr in combination with 1 mM OA or DMSO control treatment for 15 min. Values are expressed as mean of relative light units (RLU) ± SEM
of three independent experiments. *p<0.05 (Student’s t-test). See also Figure 6—figure supplement 1. (B) Schematic of HA-tagged PHLPP1 constructs
Figure 6 continued on next page
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promoter activity, suggesting a dominant-negative function of this segment. Co-immunoprecipita-
tion assays revealed a robust interaction of STAT1 with the immunoprecipitated NTE of PHLPP1, in
contrast to barely detectable binding of STAT1 to PHLPP1 lacking the NTE (Figure 7B). Intermediate
binding was observed between STAT1 and full-length PHLPP1. Quantification of three independent
experiments revealed that the isolated NTE of PHLPP1 binds STAT1 approximately five times more
Figure 6 continued
used in this study: the PP2C domain of PHLPP1 (PP2C), nuclear targeted PP2C with NLS (NLS- PP2C), NLS-PP2C with active site residues Asp1210 and
Asp1413 mutated to Ala (NLS-PP2C DDAA), and full-length PHLPP1 (PHLPP1). (C) Luciferase reporter assay in HEK-293T cells over-expressing GAS
luciferase reporter in combination with either vector control (vector, black) or the constructs described in (B) and treated with 10 ng/ml IFNg for 0, 1, 6,
or 24 hr. Values are expressed as mean RLU ± SEM of four independent experiments. All data points at 24 hr were significant against each other except
for vector to PP2C, vector to NLS-PP2C DDAA, P1 to NLS-PP2C, and PP2C to NLS-PP2C DDAA. *p<0.05, **p<0.01 (Student’s t-test). (D) Schematic
showing position and sequence of bipartite NLS in the NTE, and NLS mutants used in this study. (E) HeLa cells over-expressing the constructs used in
Figure 6D were stained for HA (green), a-Tubulin (red), and DAPI (blue). Scale bar indicates 15 mm. (F) The Nuclear to Cytoplasmic ratio was calculated
for each construct (300 cells per construct) and values are expressed as mean ± SEM. All data points were significant against each other except for
NLS1 to NLS2, and NLS2 to NLS1/2. **p<0.01, n.s. – non-significant (Student’s t-test). (G) Luciferase reporter assay in HEK-293T cells over-expressing a
GAS luciferase reporter in combination with either vector control (vector, black) or the constructs described in (D) however in the context of a full-length
PHLPP1 and treated with 10 ng/ml IFNg for 0, 1, 6, or 24 hr. Values are expressed as mean RLU ± SEM of eight independent experiments. *p<0.05,
**p<0.01, n.s. - non-significant (Student’s t-test).
DOI: https://doi.org/10.7554/eLife.48609.007
The following figure supplements are available for figure 6:
Figure supplement 1. STAT1 phosphorylation and transcriptional activity are insensitive to okadaic acid.
DOI: https://doi.org/10.7554/eLife.48609.008
Figure supplement 2. Luciferase reporter assay in HEK-293T cells over-expressing GAS luciferase reporter and treated with 10 ng/ml IFNg for 0, 1, 6, or
24 hr followed by 250 nM Go¨6983 for 10 min, 1 mM staurosporine for 30 min, or DMSO control.
DOI: https://doi.org/10.7554/eLife.48609.009
Figure supplement 3. The phosphatase activity of PHLPP1 is important for the regulation of STAT1 activity.
DOI: https://doi.org/10.7554/eLife.48609.010
Figure supplement 4. PHLPP1 has an NES.
DOI: https://doi.org/10.7554/eLife.48609.011
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Figure 7. STAT1 associates with the N-Terminal Extension of PHLPP1. (A) Luciferase reporter assay in HEK-293T cells over-expressing GAS luciferase
reporter in combination with either vector control (Vector, black), PHLPP1 NTE (NTE, green), PHLPP1DNTE (blue), or PHLPP1 (red) and treated with 10
ng/ml IFNg for 0, 1, 6, or 24 hr. Values are expressed as mean of RLU ± SEM of five independent experiments. All data points at 24 hr were significant
against each other except for vector to PHLPP1DNTE, and PHLPP1DNTE to PHLPP1. *p<0.05, **p<0.01, ***p<0.001 (Student’s t-test). (B) Western blot
analysis of detergent-solubilized lysate of HEK-293T cells transfected with vector control (Vector), HA-tagged NTE of PHLPP1 (HA-NTE), PHLPP1 with
the NTE deleted (HA-P1DNTE) or full-length PHLPP1 (HA-P1) and immunoprecipitated (IP) using HA antibody; blots were probed for co-IP of STAT1 tag
using GFP antibody. (C) Quantification of GFP-STAT1 IP divided by HA IP and normalized to HA-NTE IP. Values are expressed as mean ± SEM of three
independent experiments. ***p<0.001, ****p<0.0001 (Student’s t-test).
DOI: https://doi.org/10.7554/eLife.48609.012
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strongly than full-length PHLPP1 and 26 times more strongly than PHLPP1 lacking the NTE
(Figure 7C). These data reveal that the NTE of PHLPP1 interacts with STAT1 and reduces its pro-
moter activity.
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Figure 8. Proposed model for PHLPP1-dependent suppression of STAT1 activity. Binding of IFNg to IFN receptors results in their dimerization and
phosphorylation, promoting the recruitment of JAK, which phosphorylates STAT1 on Tyr701. This promotes the dimerization of STAT1 and its
translocation into the nucleus where it binds the GAS promoter to allow the transcription of inflammatory response genes. Activity of STAT1 is
enhanced by phosphorylation on Ser727. However, nuclear-localized PHLPP1, which binds STAT1 via its N-terminal extension, tunes the activity of
STAT1 by directly dephosphorylating this site to keep activity finely controlled. Loss of PHLPP1 results in poor resolution of inflammatory response. The
nuclear localization of PHLPP1 is controlled by a bipartite NLS (pink rectangles) in the NTE (green line) and an NES (purple rectangle) in the segment
between the LRR (gray oval) and the PP2C domain (red oval).
DOI: https://doi.org/10.7554/eLife.48609.013
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Discussion
The finding that Phlpp1-/- mice are protected from LPS-induced death allowed us to identify PHLPP1
as a physiologically relevant phosphatase in the overall innate immune response. It is likely that this
immunoregulatory phenotype reflects roles of PHLPP1 in several immune cell types, and future stud-
ies of mice with cell-specific deletions of Phlpp1 will be of great interest. Investigation of Phlpp1-/-
macrophages indicates a significant role in counter-regulation of STAT1-dependent transcription
that emerges as a secondary response to TLR4 ligation. Our mechanistic analyses show that PHLPP1
dephosphorylates STAT1 on a key regulatory site to suppress its transcriptional activity towards an
array of genes involved in mounting an inflammatory response to IFNg. Specifically, PHLPP1 directly
dephosphorylates Ser727 on STAT1 in vitro and specifically suppresses phosphorylation of Ser727,
but not Tyr701, on STAT1 in cells, correlating to decreased transcriptional activity of STAT1 at one
of its major binding sites, the GAS promoter. The intrinsic catalytic activity and nuclear localization
of PHLPP1 is required for this transcriptional regulation; while the isolated PP2C domain is not effi-
cient in suppressing GAS promoter activity, forcing the PP2C domain into the nucleus is as effective
as the full-length phosphatase in controlling transcriptional activity. Nuclear localization of the full-
length enzyme is driven by a bipartite NLS we identify in the NTE. Elimination of PHLPP1 results in
global changes in KLA-dependent transcriptional regulation, with 20% of the approximately 2000
genes whose expression changes upon KLA stimulation differing by more than two-fold in BMDMs
from Phlpp1-/- mice compared to WT mice.
Phosphorylation of STAT1 on Ser727 has been proposed to occur following the binding of the
Tyr-phosphorylated STAT1 dimer to chromatin (Sadzak et al., 2008). Ser727 phosphorylation on the
C-terminal transactivation domain of STAT1 is necessary for maximal transcriptional activity. Identifi-
cation of PHLPP1 as a phosphatase that opposes this phosphorylation provides a mechanism to
counter-regulate the activity of this key transcription factor. Several lines of evidence suggest that
PHLPP1 may be the major phosphatase that controls this regulatory site. First, genetic depletion of
PHLPP1 increases both STAT1 Ser727 phosphorylation and transcriptional activity at the GAS pro-
moter, whereas PHLPP1 overexpression decreases both STAT1 Ser727 phosphorylation and tran-
scriptional activity at the promoter. Second, both the IFNg-induced phosphorylation of Ser727 and
resulting increase in transcriptional activity at the GAS promoter are insensitive to OA, a phospha-
tase inhibitor that is ineffective towards PP2C family members but highly effective towards the abun-
dant PP2A in cells. The insensitivity of STAT1 Ser727 phosphorylation to OA is consistent with
PHLPP1 directly dephosphorylating this site in cells, a reaction it catalyzes in vitro. Furthermore,
although PHLPP1 does suppress the signaling output of Akt (by dephosphorylating Ser473; see
Gao et al., 2005) and Erk (by reducing the steady-state levels of RTKs; see Reyes et al., 2014), its
effect on STAT1 is unlikely to involve either of these targets because the activities of both kinases
are sensitive to OA. Nor are the effects on Ser727 a result of PHLPP1 reducing PKC steady-state lev-
els (Baffi et al., 2019; Gao et al., 2008), as the general PKC inhibitor Go¨6983 did not alter GAS pro-
moter activity (Figure 6—figure supplement 2). Third, genetic depletion of either PHLPP1 or STAT1
has opposing effects on transcriptional targets of STAT1: whereas KLA causes a larger increase in
mRNA of Cd69, Ifit2, and Gbp5 in BMDMs from Phlpp1-/- mice compared to WT mice, a reduction
in these transcripts is observed upon STAT1 knockdown. Lastly, we have previously shown that
PHLPP1 regulates transcription of genes and binds chromatin (Reyes et al., 2014). Cumulatively,
these data are consistent with PHLPP1 being the major phosphatase to oppose the activating phos-
phorylation of STAT1 on Ser727, thereby limiting its transcriptional activity.
The interaction of PHLPP1 with STAT1, mediated by its NTE, affords fidelity and specificity in its
dephosphorylation of the transcription factor. PHLPP1 binding to STAT1 is consistent with this multi-
valent protein utilizing its protein-interaction domains to position it near its substrates, either via
direct interaction or by binding protein scaffolds, such as PDZ domain proteins that coordinate Akt
signaling (Li et al., 2011). Such coordination is essential for its dephosphorylation of relevant sub-
strates, in part due to the low catalytic activity of the phosphatase (approximately one reaction per
sec towards peptide substrates, over an order of magnitude lower than that of the related phospha-
tase PP2Ca; see Sierecki and Newton, 2014). The importance of enzyme proximity to its substrate
is best illustrated with Akt, where deletion of the last three amino acids of PHLPP1 to remove the
PDZ ligand abolishes the ability of PHLPP1 to dephosphorylate Akt in cells (Gao et al., 2005). Thus,
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binding of PHLPP1 via its NTE to STAT1 affords an efficient mechanism to restrict its activity by
directly opposing its phosphorylation in the nucleus (see Figure 8).
The regulation of STAT1 by PHLPP1 occurs in the nucleus, and we identify motifs in the phospha-
tase that control both the entry into (NLS) and exit from (NES) the nucleus. First, we identify a bipar-
tite NLS in the NTE of PHLPP1 whose integrity is necessary for the phosphatase to regulate the
transcriptional activity of STAT1. Second, we identify an NES in the segment between the LRR and
PP2C domain that drives export out of the nucleus. Under the ‘unstimulated’ conditions of our
immunofluorescence, PHLPP1 localized primarily to the cytosol, suggesting masking of the NLS and
exposure of the NES. Inputs that regulate the exposure of the NLS and NES are likely important reg-
ulators of PHLPP1 function.
Our transcriptomic data support a key role for PHLPP1 in the resolution of the inflammatory
response specific to genes downstream of type II IFN signaling pathways. This suggests the possibil-
ity that PHLPP1 can selectively discriminate between inflammatory promoters that are differentially
regulated by distinct transcription factor families. Surprisingly, over 50% of the inflammatory genes
that fail to properly resolve in the macrophages from Phlpp1-/- mice contain a consensus STAT-bind-
ing motif in their proximal promoters. Our studies have demonstrated a direct interaction between
PHLPP1 and STAT1, thus it is highly likely that PHLPP1 is recruited to gene promoters through its
association with STAT1. Elevated STAT1 occupancy and delayed dismissal kinetics of STAT1 from its
target promoters in Phlpp1-/- macrophages indicate a major function of PHLPP1-dependent dephos-
phorylation in termination of STAT1 signaling and its dismissal from chromatin.
Germline mutations that impair STAT1 function, by reducing either Tyr701 phosphorylation
(L706S) or DNA binding (Q463H and E320Q), increase the susceptibility of otherwise healthy
patients to mycobacterial and viral infection (Chapgier et al., 2006; Dupuis et al., 2001). This
increased susceptibility was proposed to arise because of reduced transcription of genes involved in
bacterial and viral immunity from the GAS and ISRE promoters, respectively. Similarly, genetic abla-
tion of Stat1 on the background of a mouse that has enhanced TLR4 signaling (because of deletion
of Il6st, a key regulator of systemic inflammatory responses during LPS-mediated endotoxemia) pro-
vides protection against LPS-induced toxemic death compared to mice with normal STAT1 levels
(Luu et al., 2014). Although the current study does not provide direct evidence that enhanced phos-
phorylation of STAT1 causes the protective effect of PHLPP1 loss on both E. coli-induced sepsis and
LPS-induced endotoxemia in mice, our data indicate that PHLPP1 inhibitors could be explored as
adjunctive therapies to antibiotics and supportive care of patients with Gram-negative sepsis, a lead-
ing cause of mortality in intensive care units.
Materials and methods
Key resources table
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Cell line
(Mus musculus)
Primary Bone Marrow
Derived Macrophage
Cells from Phlpp1+/+ mice
This paper WT BMDM male, 6–8 week old
C57BL/6 mice, Charles
River Laboratories
Cell line
(Mus musculus)
Primary Bone Marrow
Derived Macrophage
Cells from Phlpp1-/- mice
This paper Phlpp1-/- BMDM male, 6–8 week old
C57BL/6 mice, Charles
River Laboratories
Cell line
(Mus musculus)
Immortalized
MEFs from Phlpp1+/+ mice
Lloyd Trotman Lab,
CSHL, PMID: 21840483
stably expressing
shp53 and GFP
Cell line
(Mus musculus)
Immortalized
MEFs from Phlpp1-/- mice
Lloyd Trotman Lab,
CSHL, PMID: 21840483
stably expressing
shp53 and GFP
Cell line
(Homo sapiens)
HeLa ATCC CCL-2
Cell line
(Homo sapiens)
HEK-293T ATCC CRL-11268
Cell line
(Mus musculus)
NCTC clone L929 ATCC CCL-1 L cell, L-929, derivative of Strain L
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Strain, strain
background
(Escherichia coli)
E. coli K1 strain RS218 PMID: 6995336 Victor Nizet Lab,
University of California
San Diego
Strain, strain
background
(Mus musculus)
WT and littermate
control Phlpp1-/- mice
PMID: 20080691 female, 10 to 14 week
old, C57BL/6, for mouse
infection studies
Antibody anti-HA
(rat, monoclonal)
Roche 11867425001 Western Blot (1:1000)
Antibody anti-GFP
(rabbit, polyclonal)
Cell Signaling 2555 Western Blot (1:1000)
Antibody anti-STAT1
(rabbit, polyclonal)
Cell Signaling 9172 Western Blot (1:1000)
Antibody anti-STAT1 pSer727
(rabbit, polyclonal)
Cell Signaling 9177 Western Blot (1:1000)
Antibody anti-STAT1 pTyr701
(rabbit, polyclonal)
Cell Signaling 7649 Western Blot (1:1000)
Antibody anti-Erk1/2
pThr202/pTyr204
(rabbit, polyclonal)
Cell Signaling 9101 Western Blot (1:1000)
Antibody anti-Erk1/2
(rabbit, polyclonal)
Cell Signaling 9102 Western Blot (1:1000)
Antibody anti-Akt pThr308
(rabbit, polyclonal)
Cell Signaling 9275 Western Blot (1:1000)
Antibody anti-Akt
(rabbit, polyclonal)
AbCam 126811 Western Blot (1:1000)
Antibody anti-PHLPP1
(rabbit, polyclonal)
Proteintech 22789–1-AP Western Blot (1:1000)
Antibody anti-FLAG
(mouse, monoclonal)
Sigma-Aldrich F3165 Western Blot (1:1000)
Antibody anti-b-Actin
(mouse, monoclonal)
Sigma-Aldrich A2228 Western Blot (1:2000)
Antibody anti-a-tubulin
(mouse, monoclonal)
Sigma-Aldrich T6074 Western Blot (1:1000)
Antibody anti-STAT1
(rabbit, polyclonal)
Santa Cruz Biotechnology sc-345 Chromatin
Immunoprecipitation
Antibody anti-HA (mouse,
monoclonal)
BioLegend 901503 Immunoprecipitation
Antibody anti-a-tubulin
(rabbit, monoclonal)
Cell Signaling 2125 Immunofluorescence (1:200)
Antibody anti-Alexa647
(goat anti-Mouse IgG)
Life Technologies A21235 Immunofluorescence (1:500)
Antibody anti-Alexa477
(goat anti-Rabbit IgG)
Life Technologies A11034 Immunofluorescence (1:500)
Recombinant
DNA reagent
pCMV 3XFLAG-
PHLPP1 WT
This paper residues 1–1717 of PHLPP1
Recombinant
DNA reagent
pCDNA3 HA-NLS-
PHLPP1 PP2C
This paper residues 653–906 of PHLPP1
Recombinant
DNA reagent
pCDNA3 HA-NLS-PHLPP1
PP2C D1210/1413A
This paper DDAA Aspartate at residues
1210 and 1413 mutated
to Alanine
Recombinant
DNA reagent
pCDNA3 HA PHLPP1
NTE-WT
This paper residues 1–512 of PHLPP1
Recombinant
DNA reagent
pCDNA3 HA-PHLPP1
NTE-NLS1 mut.
This paper residues 1–512 of PHLPP1
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Recombinant
DNA reagent
pCDNA3 HA-PHLPP1
NTE-NLS2 mut.
This paper residues 1–512 of PHLPP1
Recombinant
DNA reagent
pCDNA3 HA-PHLPP1
NTE-NLS1/2 mut.
This paper residues 1–512 of PHLPP1
Recombinant
DNA reagent
pCDNA3 HA-NES-PHLPP1 NTE This paper residues 1–512 of PHLPP1
Recombinant
DNA reagent
pCDNA3 HA-PHLPP1 DNTE PMID: 15808505 Addgene: 22404 residues 513–1717 of PHLPP1
Recombinant
DNA reagent
pCDNA3 HA-PHLPP1NES-PHLPP1 NTE This paper residues 1–512 of PHLPP1
Sequence-
based reagent
Stat1 SMART
siRNA pools
Dharmacon L-058881
Sequence-
based reagent
Control SMART
siRNA pools
Dharmacon D-001810-10-05
Peptide,
recombinant protein
murine IFNg PeproTech 315–05 10 ng/mL
Peptide,
recombinant protein
human IFNg PeproTech 300–02 10 ng/mL
Peptide,
recombinant protein
recombinant STAT1 Biosource PHF0011 0.3 uM
Peptide,
recombinant protein
recombinant
human Cdk1/CyclinB
Millipore 14–450 0.2 uM
Peptide,
recombinant protein
E. coli O111:B4 LPS Sigma-Aldrich L4391
Chemical
compound, drug
Okadaic Acid (OA) Millipore 459616 1 mM
Chemical
compound, drug
Go¨6983 Calbiochem 365251 250 nM
Chemical
compound, drug
Staurosporine Calbiochem 569397 1 mM
Chemical
compound, drug
KLA Avanti Polar Lipids 699500 100 ng/mL
Chemical
compound, drug
RO-3306 Enzo ALX-270–463 144 uM
Commercial
assay or kit
Dual-Glo Luciferase
Assay System
Promega E2940
Commercial
assay or kit
IL-6 ELISA Kit R and D Systems DY406
Commercial
assay or kit
IL-1b ELISA Kit R and D Systems DY401
Commercial
assay or kit
IL-10 ELISA Kit R and D Systems DY417
Materials and antibodies
OA (459616) was purchased from Millipore. Go¨6983 (365251) and staurosporine (569397) were pur-
chased from Calbiochem. Antibody against HA (11867425001) was purchased from Roche; antibod-
ies against GFP (2555), STAT1 (9172), phosphorylated Ser727 on STAT1 (9177), phosphorylated
Tyr701 on STAT1 (7649), phosphorylated Thr202/Tyr204 on Erk1/2 (9101), total Erk1/2 (9102), and
phosphorylated Thr308 on Akt (9275) were purchased from Cell Signaling. Antibody against total
Akt (126811) was obtained from AbCam. Antibodies against PHLPP1 were purchased from Cosmo
(KIAA0606) and Proteintech (22789–1-AP); antibodies against FLAG (F3165), b-Actin (A2228), and a-
tubulin (T6074) were purchased from Sigma-Aldrich. The pcDNA3 HA-tagged PHLPP1 and PHLPP2
constructs for mammalian cell expression were described previously (Brognard et al., 2007;
Cohen Katsenelson et al. eLife 2019;8:e48609. DOI: https://doi.org/10.7554/eLife.48609 16 of 23
Research article Biochemistry and Chemical Biology Immunology and Inflammation
Gao et al., 2008; Gao et al., 2005). Full-length PHLPP1 was cloned into pCMV 3xFLAG vector
(Sigma-Aldrich, E4401). An NLS was cloned to the N-terminus of the PP2C domain of PHLPP1. A
double mutant of NLS-PP2C at residues D1210A and D1413A was cloned by site-directed mutagen-
esis. The HA-tagged PHLPP1 N-terminal extension (PHLPP1 NTE), residues 1–512, was cloned into
pcDNA3 vector (Invitrogen). The NLS1 and NLS2 mutations were cloned by site-directed mutagene-
sis into HA-PHLPP1 NTE. The NES from PKI (LALKLALDI) was cloned into the N-terminus of HA-
PHLPP1 NTE. The PHLPP1 NES (residues 1125–1134, LPPKLQELDL) was subcloned directly down-
stream of the HA-tag in HA-PHLPP1 NTE, to generate HA-PHLPP1NES-NTE.
Isolation and treatment of macrophages
Primary BMDM cells were isolated from male 6- to 8-week-old C57BL/6 mice (Charles River Labora-
tories). BMDMs were obtained by PBS flush of femurs and tibias (Weischenfeldt and Porse, 2008),
red blood cells lysed, and remaining cells plated in RPMI 1640 supplemented with 20% fetal bovine
serum (FBS, Gibco, cat. 12657–029), 30% L-cell conditioned medium, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine. Cells were seeded in non-tissue culture treated Optilux Petri
dishes (BD Biosciences), incubated at 37˚C in a 5% CO2 atmosphere for 7 days, then treated with
100 ng/ml KLA (699500, Avanti Polar Lipids) for noted times. Peritoneal macrophages were collected
by flushing mouse peritoneal cavities with PBS following 48 hr post peritoneal injection with 3 ml of
thioglycolate (Ray and Dittel, 2010).
Cell culture
MEFs from WT or Phlpp1-/- mice stably expressing shp53 were a kind gift from Lloyd Trotman
(CSHL) and have been described previously (Chen et al., 2011); MEFs, HEK-293T, and HeLa (ATCC)
cells were grown in Dulbecco’s modified Eagle medium (DMEM, 10–013-CV, Corning) supplemented
with 10% fetal bovine serum (S11150, Atlanta biologicals) and 1% penicillin/streptomycin (15140–
122, Gibco) at 37˚C in 5% (vol/vol) CO2. Cells used were periodically tested for Mycoplasma contam-
ination using a PCR-based protocol (Uphoff and Drexler, 2011) and showed no evidence of
contamination.
mRNA isolation and qPCR analysis
RNA was purified using Direct-zol RNA Miniprep Kits (Zymo Research) from triplicate experiments
and quantified using a NanoDrop Spectrophotometer (ThermoFisher Scientific). RNA was either
reverse transcribed into cDNA for quantitative real-time PCR using gene-specific primers or used for
next-generation library preparation. For cDNA generation, one mg of total mRNA was reverse tran-
scribed using the SuperScript III Reverse Transcriptase (ThermoFisher Scientific). The resulting cDNA
(25 ng) was used to perform real-time PCR using SYBR Green Master Mix (ThermoFisher Scientific)
and 50 nM mix of forward and reverse primers. The real-time PCR values for individual genes were
normalized to the house keeping gene, 36B4, using the DDCT method (Livak and Schmittgen,
2001). The primer sequences used in this study are:
36B4_qPCR_F AATCTCCAGAGGCACCATTG
36B4_qPCR_R CCGATCTGCAGACACACACT
Cd69_qPCR_F CTATCCCTTGGGCTGTGTTAAT
Cd69_qPCR_R ACATGGTGGTCAGATGATTCC
Ifit2_qPCR_F GAGTTTGAGGACAGGGTGTTTA
Ifit2_qPCR_R AGACCTCTGCAGTGCTTTAC
Gbp5_qPCR_F GGAAGTGCTGCAGACCTATT
Gbp5_qPCR_R GCTCTTTCTTGTTCCGCTTTAC
Next-generation sequence library preparation and analysis
Libraries were prepared from two biological replicates per condition. RNA-Seq libraries were pre-
pared as previously described (Kaikkonen et al., 2013). Sequencing libraries were prepared using
magnetic beads similar to described previously using barcoded adapters (NextFlex, Bioo Scientific)
(Garber et al., 2012). Libraries were sequenced for 36 or 50 cycles on an Illumina Genome Analyzer
II or HiSeq 2000, respectively, according to the manufacturer’s instructions. mRNA-Seq results were
trimmed to remove A-stretches originating from the library preparation. Each sequence tag returned
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by the Illumina Pipeline was aligned to the mm10 assembly using ELAND allowing up to two mis-
matches. Only tags that mapped uniquely to the genome were considered for further analysis. Peak
finding, MOTIF discovery, and downstream analysis was performed using HOMER, a software suite
created for analysis of high-throughput sequencing data (Heinz et al., 2010). Detailed instructions
for analysis can be found at http://homer.ucsd.edu/homer/. Data visualization was performed using
Microsoft Excel, JavaTreeGraph and software packages available in R.
RNA interference experiments
SMART siRNA pools for examined genes were purchased from Dharmacon (Control: D-001810-10-
05, Stat1: L-058881). Thioglycollate-elicited peritoneal macrophages were transfected with 30 nM
siRNA for 48 hr using Deliver X (Affymetrix) according to the manufacturer’s instructions prior to
being stimulated with KLA for designated times.
Chromatin immunoprecipitation
ChIP assays were performed as described before (Stender et al., 2017). Cells were crosslinked with
2 mM disuccinimidyl glutarate for 30 min prior to 10 min treatment with 1% formaldehyde. The anti-
bodies used in these studies were: STAT1 (sc-345, Santa Cruz Biotechnology). For the precipitations
protein A Dynabeads (10003D, Invitrogen) were coated with antibody prior to pulldown and excess
antibody was washed away. Pulldowns occurred while rotating for 16 hr at 4˚C. Beads were then
washed with TSE I (20 mMTris/HCl pH 7.4 at 20˚C, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 2 mM
EDTA), twice with TSE III (10 mM Tris/HCl pH 7.4 at 20˚C, 250 mM LiCl, 1% IGEPAL CA-630, 0.7%
Deoxycholate, 1 mM EDTA), and twice with TE followed by elution from the beads using elution
buffer (0.1 M NaHCO3, 1% SDS). Elutions were subsequently de-crosslinked overnight at 65˚C and
DNA was purified using ChIP DNA Clean and Concentrator (Zymo Research) and DNA was used for
qPCR. The primer sequences used in this study are:
Cd69_ChIP_F TCCCTGCTGTCTGAAATGTG
Cd69_ChIP_R GTGGAAGGATGTCTTCGATTCT
Ifit2_ChIP_F GCATTGTGCAAGGAGAATTCTATG
Ifit2_ChIP_R TTCCGGAATTGGGAGAGAGA
Gbp5_ChIP_F TAAACAGCGCTTGAAACAATGA
Gbp5_ChIP_R AGGCTTGAATGTCACTGAACTA
Luciferase assay
Cells were plated in a 96-well plate and transfected when approximately 80% confluent. Transfec-
tions of pRL-CMV encoding Renilla luciferase (Heinz et al., 2010), together with a firefly luciferase
promoter-reporter construct containing eight GAS consensus sequences (Horvai et al., 1997), con-
trol vector, or the indicated PHLPP constructs, were performed using Lipofectamine 3000 reagent
(Invitrogen, L3000) for MEFs or Fugene six reagent (Promega, E269A) for HEK-293T cells. Cells were
treated with murine or human IFNg (PeproTech, 315–05, 300–02, respectively) for the indicated
times at 37˚C and activity was measured using the Dual-Glo Luciferase Assay System (Promega,
E2940) in a Tecan Infinite M200 Pro multi-well plate reader. Promoter activity was corrected for the
luciferase activity of the internal control plasmid, pRL-CMV, and Relative Response Ratios (RRR) were
calculated.
Immunoprecipitation and western blot
DNA was transfected into HEK-293T cells using FuGene 6. Cells were collected 24 hr post-transfec-
tion and then lysed in a buffer containing 50 mM Na2HPO4 (pH 7.5), 1 mM sodium pyrophosphate,
20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% SDS, 1 mM DTT, 1 mM microcystin, 20 mM benzamidine,
40 mg/ml leupeptin, and 1 mM PMSF and then were sonicated briefly. For co-immunoprecipitation,
cells were lysed and the detergent-solubilized cell lysates were incubated with an anti-HA antibody
(BioLegend, 901503) at 4˚C overnight. Samples were incubated with protein A/G PLUS-Agarose
(Santa Cruz Cat sc-2003) for 1 hr at 4˚C and washed three times in lysis buffer containing 0.3 M NaCl
and 0.1% Triton X 100. Bound proteins and lysates were separated by SDS/PAGE gel and analyzed
by western blot.
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Immunofluorescence
HeLa cells were plated on glass coverslips and transfected using FuGene 6. 24 hr after transfection,
cells were fixed with 4% paraformaldehyde for 20 min at room temperature, followed by fixation
with 100% methanol for 3 min at  20˚C. Cells were permeabilized and blocked in 0.3% Triton X
100% and 3% BSA for 30 min at room temperature, followed by three 5 min washes in PBS-T. Pri-
mary antibodies were diluted at the following dilutions: mouse anti-HA, 1:500; rabbit anti-a-tubulin
(Cell Signaling, 2125), 1:200. Secondary antibodies were diluted at the following dilutions: Alexa647
anti-mouse (Life Technologies, A21235), 1:500; Alexa488 anti-rabbit (Life Technologies, A11034),
1:500. Coverslips were mounted onto slides with ProLong Diamond Antifade Mountant with DAPI
(ThermoFisher, P36966). Images were acquired on a Zeiss Axiovert 200M microscope (Carl Zeiss
Microimaging Inc) using an iXon Ultra 888 EMCCD camera (ANDOR) controlled by MetaFluor soft-
ware (Molecular Devices) and analyzed on ImageJ (NIH). The Nuclear to Cytoplasmic ratio was calcu-
lated as follows: the mean signal intensity was measured for a region of the nucleus and cytoplasm
for each cell, and the mean signal intensity of the background was subtracted from these values.
Then the Nuclear to Cytoplasmic ratio was calculated by dividing the background subtracted mean
signal intensity for the nuclear signal by the background subtracted value for the cytoplasmic signal.
In vitro phosphatase assay
pCMV 3xFLAG PHLPP1 was transfected into HEK-293T cells plated in four 10 cm plates (approxi-
mately 9  106 cells per plate, 80% transfection efficiency) using Fugene 6. Cells were collected 48
hr post-transfection and lysed in a buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X 100, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 1 mM DTT, 1
mM PMSF, 1 mM microcystin, 20 mM benzamidine, and 40 mg/ml leupeptin. The detergent-solubi-
lized cell lysates were incubated with anti-FLAG M2 affinity gel (30 ml per plate, Sigma-Aldrich,
A2220) for 1 hr at 4˚C, washed four times in lysis buffer and the beads were resuspended in 40 ml
200 mM Tris, 4 mM DTT, 20 mM MnCl2 for use in in vitro phosphatase assay. STAT1 (0.3 mM) (Bio-
source, PHF0011) was phosphorylated in vitro by incubation with recombinant human cdk1/cyclinB
(0.2 mM) (Millipore, 14–450) at 30˚C for 90 min in the presence of 1 mM ATP, and 1 X PK buffer
(NEB, B6022) containing 50 mM Tris, 10 mM MgCl2, 0.1 mM EDTA, 2 mM DTT, 0.01% Brij, pH 7.5,
and the reaction was quenched by addition of 144 mM CDK1 inhibitor RO3306 (Enzo, ALX-270–463).
Phosphorylated STAT1 substrate was added to 1/4 vol of beads with bound PHLPP1 (or to lysis
buffer control) and reactions were allowed to proceed for an additional 120 min at 30˚C. For the
zero minute time point, beads were added after the 120 min incubation and all reactions were
immediately quenched with 4xSB (sample buffer). Samples were analyzed by western blot.
Mouse infection and endotoxin challenge
Bacterial sepsis in mice was induced by injection of E. coli K1 strain RS218 and LPS endotoxemia was
induced by injection of purified E. coli O111:B4 LPS (Sigma-Aldrich). The E. coli culture was grown
overnight in Luria broth (LB) medium (Hardy Diagnostics) at 37˚C with shaking. The bacterial culture
was diluted 1:50 in fresh LB, grown to mid-log phase, washed twice with PBS and reconstituted in
PBS to yield the appropriate inoculum. For survival experiments, 10 to 14 week-old female C57BL/6
WT and littermate control Phlpp1-/- mice were injected i.p. with 5  107 colony forming units (cfu) E.
coli or 15 mg/kg LPS and mouse survival recorded for 10 days following injection. For measurement
of serum IL-6, IL-10 and IL-1b levels, mice were injected with 10 mg/kg LPS, and at 4, 8, 12 and 24 hr
after injection, 80 ml of blood was collected by submandibular bleeding using a lancet into a serum
separating blood collection tubes (BD) that were spun at 1500  g for 10 min to separate serum.
Serum cytokines were quantified by specific ELISA (R and D) following the manufacturer’s protocol.
All protocols for mouse experiments were conducted in accordance with the institutional guidelines
and were approved by the Institutional Animal Care and Usage Committee (IACUC) at the University
of California, San Diego.
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